News:

Just a reminder: if you haven't signed in for six months or more, please do so if you wish to remain active...no need to post, just sign in so we know you're still interested.

Main Menu

Seletalisib Phase II Trial published

Started by markt, November 18, 2019, 11:26:30 AM

Previous topic - Next topic
Print
Go Down Pages1
User actions

markt

November 18, 2019, 11:26:30 AM Last Edit: November 18, 2019, 11:33:42 AM by markt
No longer relegated to being studied in murine models...

https://ard.bmj.com/content/78/Suppl_2/1692.2

Seletalisib is a potent, selective oral inhibitor of phosphoinositide-3 kinase delta (PI3Kδ). Preclinical data have shown that the PI3Kδ pathway is upregulated within salivary glands of patients with PSS and contributes to disease pathogenesis.   

https://clinicaltrials.gov/ct2/show/NCT02610543

https://sjogrenssyndromenews.com/2019/01/15/seletalisib-improves-saliva-flow-lowers-inflammation/

It will be interesting to see what happens in lager Phase-III trials...
Print
Go Up Pages1
User actions